Placental abruption could increase risk of cardiovascular disease in women
Cardiovascular disease (CVD) is the leading cause of death globally, with the World Health Organization (WHO) estimating that 19.8 million…
Cardiovascular
-
-
Smartwatches could aid in monitoring heart failure exacerbations
Heart failure (HF) is a substantial global health problem that is characterised by significant mortality and poor quality of life.…
-
ACC 2026: pooled analysis supports early dapagliflozin use in acute HF care
On 30 March, at this year’s American College of Cardiology (ACC) Scientific Session, during a poster contributions session on the…
-
Theravance shuts down R&D efforts and cuts workforce by half after Phase III trial failure
Theravance Biopharma is restructuring its R&D organisation and cutting its workforce by approximately half after its rare disease blood pressure…
-
Bayer’s Factor XIa inhibitor reduces repeat stroke risk by 26% in pivotal trial
Bayer’s investigational, once-daily, oral Factor XIa inhibitor asundexian reduced the risk of recurrent ischemic stroke by 26% in a pivotal…
-
JPM26: Eli Lilly highlights Lp(a) drugs as cardiovascular growth focus
At the 44th Annual JP Morgan Healthcare conference 2026, Eli Lilly highlighted lepodisiran and muvalaplin as the key drugs in…
-
BioAge’s NLRP3 inhibitor shows potential to reduce cardiovascular risk
BioAge’s NLRP3 inhibitor has shown potential to reduce high-sensitivity C-reactive protein (hsCRP), a key marker of cardiovascular risk, in an…
-
BMS and Johnson & Johnson terminate Phase III ACS trial due to likely failure
Editor’s note: This article has been updated to clarify that the collaboration was with Johnson & Johnson, not AstraZeneca as…
-
AHA 2025: satralizumab shows benefit in immune-driven pulmonary arterial hypertension
At the 2025 American Heart Association (AHA) Scientific Sessions in New Orleans, investigators from Japan presented results from the SATISFY-JP…
-
Long-term benefit of Amgen’s Repatha in reducing MACE shown in Phase III trial
Amgen's Repatha (evolocumab) has shown benefit in a long-term study in reducing cardiovascular incidents in patients without a prior history…
